chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 22.0
Sex: F
Vaccine: TDAP
Symptoms: Asthenia, Diarrhoea, Fatigue, Headache, Myalgia
Clinical narrative: Had TDAP 1/19/2010 @ 1400. Symptoms including fatigue, body ache, fever, myalgia and headache began 1/19/2010 at 8pm. Diarrhea beginning 1/20/2010 Temperature 97.2 as of 1/12/2010 4pm. weakness and diarrhea as of 1/21/10.
Age: 22.0
Sex: F
Vaccine: TDAP
Symptoms: Pain, Pyrexia
Clinical narrative: Had TDAP 1/19/2010 @ 1400. Symptoms including fatigue, body ache, fever, myalgia and headache began 1/19/2010 at 8pm. Diarrhea beginning 1/20/2010 Temperature 97.2 as of 1/12/2010 4pm. weakness and diarrhea as of 1/21/10.
Age: 64.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site pain, Joint range of motion decreased
Clinical narrative: Lt upper arm pain x3 months (started after vaccine administered per pt.) Decreased ROM of arm per patient. Referred to health department for further details.
Age: 24.0
Sex: M
Vaccine: ANTH, SMALL, TYP
Symptoms: Injection site erythema
Clinical narrative: This case was received on 11 January 2009 via a search of the VAERS database (321762). It was originally reported to VAERS by another manufacturer (Emergent Biosolutions). A 24-year-old male patient received the following vaccinations on 31 July 2008: smallpox (trade name and manufacturer unknown, lot not reported). TYPHIM Vi (lot not reported), and BIOTRHAX (Lot not reported). On 09 August 2008, nine days after receiving the vaccines, he developed redness that spread around his upper left arm. The patient recovered from the event; however a date of recovery was no reported. No additional information was provided.
Age: 58.0
Sex: M
Vaccine: ANTH, SMALL, TYP
Symptoms: Injection site mass, Injection site pain, Musculoskeletal pain, Musculoskeletal stiffness, Sleep disorder
Clinical narrative: This case was received on 11 January 2009 via a search of the database (322305). It was originally reported to VAERS by another manufacturer (manufacturer unknown). A 58-year-old male patient received the following vaccinations on 03 March 2008: a percutaneous injection of smallpox (trade name and manufacturer unknown, lot not reported), an intramuscular injection of TYPHIM VI, lot not reported, and an intramuscular left deltoid injection of BIOTHRAX, lot not reported. On 05 April 2008, 33 days after receiving the vaccines (also reported as 32 days to onset), the patient developed a lump and ache in his left shoulder. According to the patient, one of the shots received was anthrax which was administered directly into the left shoulder muscle and he developed the usual lump in the shoulder. The patient subsequently received his "two remaining shots" (specific vaccines not reported) in the right shoulder area, in the back of the triceps. Following those two injections, he experienced a lump and some stiffness which dissipated without incident, however the stiffness and aching returned (date not reported). The patient was five and a half months into his tour and the ache in the left shoulder continued. They were evaluated by a medical professional on 29 April and 13 May (year not reported) and were prescribed MOTRIN, meloxicam and TORADOL. At that time, the ache was described as improving (probably 90 percent) during the day with routine usage, but the ache returned "full strength" at night when the shoulder was inactive which woke the patient up several times at night if he rolled around. In the morning, the shoulder was very stiff, but began to feel better in a couple of hours. the patient now reported an ache in both shoulders in the morning. The patient played basketball and volleyball and his physician felt activity would be good. The patient stated that they mentioned an x-ray, but that everyone agreed this was a soft tissue problem, not a problem with the rotator "cup". An MRI had not been performed. The patient found that MOTRIN (800mg) helped with the stiffness, especially overnight. The event outcome was reported to have "required intervention to prevent permanent impairment/damage". The patient's recovery status was not reported.
Age: 33.0
Sex: F
Vaccine: ANTH, HEP, MMR, SMALL, TYP
Symptoms: Biopsy skin normal, Erythema nodosum, Headache, Injection site induration, Injection site pain
Clinical narrative: This case was received on 11 January 2009 via a search of the database (VAERS identification number 322629). It was originally reported to VAERS by an unknown manufacturer. A 33-year-old female patient received the following vaccinations on 26 March 2003: a second dose of TYPHIM VI, lot number not reported, route unknown and site of administration not provided, a first intramuscular injection of BIOTHRAX, manufacturer BioPort Corp, lot number and site of administration not provided, a first percutaneous injection of DRYVAX, manufacturer Wyeth, lot number and site of administration not provided, a second dose of "HEP B" vaccine (trade name and manufacturer name unknown, lot number not reported, route unknown, and site of administration not provided), and a first dose of measles + mumps + rubella vaccine (trade name and manufacturer name unknown, lot number not reported, route unknown, and site of administration not provided). At an unspecified amount of time after receiving the vaccinations, the patient reported that at first, the area of injection (site not provided) was hard and hot, and there was a golf ball size lesion on the arm that was very painful. The patient also experienced fever and headache. The patient was subsequently diagnosed with erythema nodosum. Approximately in the eight month of 2003 (around September 2003) after receiving the vaccinations, the patient developed a rash on her scalp and though it was nothing, but it worsened and she was evaluated by a dermatologist. A punch biopsy was performed and the patient was diagnosed with psoriasis. The patient required intervention for the adverse events; however treatments prescribed and other possible diagnostic tests performed were not provided. The patient reported that these events happened after every anthrax shot. It was noted the patient had subsequently received a second dose of anthrax on 09 April 2003, a third dose on 24 April and the fourth dose on 29 September 2003. The recovery status of the patient was not reported. Documents held by sender: None.
Age: 33.0
Sex: F
Vaccine: ANTH, HEP, MMR, SMALL, TYP
Symptoms: Injection site reaction, Injection site warmth, Psoriasis, Pyrexia, Skin lesion
Clinical narrative: This case was received on 11 January 2009 via a search of the database (VAERS identification number 322629). It was originally reported to VAERS by an unknown manufacturer. A 33-year-old female patient received the following vaccinations on 26 March 2003: a second dose of TYPHIM VI, lot number not reported, route unknown and site of administration not provided, a first intramuscular injection of BIOTHRAX, manufacturer BioPort Corp, lot number and site of administration not provided, a first percutaneous injection of DRYVAX, manufacturer Wyeth, lot number and site of administration not provided, a second dose of "HEP B" vaccine (trade name and manufacturer name unknown, lot number not reported, route unknown, and site of administration not provided), and a first dose of measles + mumps + rubella vaccine (trade name and manufacturer name unknown, lot number not reported, route unknown, and site of administration not provided). At an unspecified amount of time after receiving the vaccinations, the patient reported that at first, the area of injection (site not provided) was hard and hot, and there was a golf ball size lesion on the arm that was very painful. The patient also experienced fever and headache. The patient was subsequently diagnosed with erythema nodosum. Approximately in the eight month of 2003 (around September 2003) after receiving the vaccinations, the patient developed a rash on her scalp and though it was nothing, but it worsened and she was evaluated by a dermatologist. A punch biopsy was performed and the patient was diagnosed with psoriasis. The patient required intervention for the adverse events; however treatments prescribed and other possible diagnostic tests performed were not provided. The patient reported that these events happened after every anthrax shot. It was noted the patient had subsequently received a second dose of anthrax on 09 April 2003, a third dose on 24 April and the fourth dose on 29 September 2003. The recovery status of the patient was not reported. Documents held by sender: None.
Age: 33.0
Sex: F
Vaccine: ANTH, HEP, MMR, SMALL, TYP
Symptoms: Vaccine positive rechallenge
Clinical narrative: This case was received on 11 January 2009 via a search of the database (VAERS identification number 322629). It was originally reported to VAERS by an unknown manufacturer. A 33-year-old female patient received the following vaccinations on 26 March 2003: a second dose of TYPHIM VI, lot number not reported, route unknown and site of administration not provided, a first intramuscular injection of BIOTHRAX, manufacturer BioPort Corp, lot number and site of administration not provided, a first percutaneous injection of DRYVAX, manufacturer Wyeth, lot number and site of administration not provided, a second dose of "HEP B" vaccine (trade name and manufacturer name unknown, lot number not reported, route unknown, and site of administration not provided), and a first dose of measles + mumps + rubella vaccine (trade name and manufacturer name unknown, lot number not reported, route unknown, and site of administration not provided). At an unspecified amount of time after receiving the vaccinations, the patient reported that at first, the area of injection (site not provided) was hard and hot, and there was a golf ball size lesion on the arm that was very painful. The patient also experienced fever and headache. The patient was subsequently diagnosed with erythema nodosum. Approximately in the eight month of 2003 (around September 2003) after receiving the vaccinations, the patient developed a rash on her scalp and though it was nothing, but it worsened and she was evaluated by a dermatologist. A punch biopsy was performed and the patient was diagnosed with psoriasis. The patient required intervention for the adverse events; however treatments prescribed and other possible diagnostic tests performed were not provided. The patient reported that these events happened after every anthrax shot. It was noted the patient had subsequently received a second dose of anthrax on 09 April 2003, a third dose on 24 April and the fourth dose on 29 September 2003. The recovery status of the patient was not reported. Documents held by sender: None.
Age: 41.0
Sex: M
Vaccine: ANTH, SMALL, TYP
Symptoms: Arthralgia, Bone pain, Cardiovascular disorder, Erectile dysfunction, Gastrointestinal disorder
Clinical narrative: This case was received on 11 January 2009 via a search of the database (reference number 325735. It was originally reported to VAERS by another manufacturer (manufacturer unknown). A 41 year old patient received the following vaccinations on 01 March 1991: TYPHIM VI, lot number and route not reported, DRYVAX, manufacturer Wyeth, lot number not reported, percutaneously, BIOTHRAX, lot number and route not reported. Following the vaccination, on an unspecified date, the patient experienced great pain in all joints including wrists, shoulders, cervical and lumbosacral degenerative joint disease, neck, bones, mental disorders, erectile dysfunction, both rotator cuffs shattered, gastrointestinal disorder, cardiovascular disease, can't sleep and subjected to many medications. The event was reported as life-threatening, required intervention to prevent permanent damage, and disability. List of Documents held by sender: None
Age: 41.0
Sex: M
Vaccine: ANTH, SMALL, TYP
Symptoms: Insomnia, Mental disorder, Musculoskeletal pain, Neck pain, Osteoarthritis
Clinical narrative: This case was received on 11 January 2009 via a search of the database (reference number 325735. It was originally reported to VAERS by another manufacturer (manufacturer unknown). A 41 year old patient received the following vaccinations on 01 March 1991: TYPHIM VI, lot number and route not reported, DRYVAX, manufacturer Wyeth, lot number not reported, percutaneously, BIOTHRAX, lot number and route not reported. Following the vaccination, on an unspecified date, the patient experienced great pain in all joints including wrists, shoulders, cervical and lumbosacral degenerative joint disease, neck, bones, mental disorders, erectile dysfunction, both rotator cuffs shattered, gastrointestinal disorder, cardiovascular disease, can't sleep and subjected to many medications. The event was reported as life-threatening, required intervention to prevent permanent damage, and disability. List of Documents held by sender: None
Age: 41.0
Sex: M
Vaccine: ANTH, SMALL, TYP
Symptoms: Rotator cuff syndrome
Clinical narrative: This case was received on 11 January 2009 via a search of the database (reference number 325735. It was originally reported to VAERS by another manufacturer (manufacturer unknown). A 41 year old patient received the following vaccinations on 01 March 1991: TYPHIM VI, lot number and route not reported, DRYVAX, manufacturer Wyeth, lot number not reported, percutaneously, BIOTHRAX, lot number and route not reported. Following the vaccination, on an unspecified date, the patient experienced great pain in all joints including wrists, shoulders, cervical and lumbosacral degenerative joint disease, neck, bones, mental disorders, erectile dysfunction, both rotator cuffs shattered, gastrointestinal disorder, cardiovascular disease, can't sleep and subjected to many medications. The event was reported as life-threatening, required intervention to prevent permanent damage, and disability. List of Documents held by sender: None
Age: 43.0
Sex: M
Vaccine: ANTH, FLUN3, HEP, SMALL, TYP
Symptoms: Chest discomfort, Chest pain, Echocardiogram, Electrocardiogram abnormal, Pericarditis
Clinical narrative: This case was received on 17 December 2008 via a search of the database (reference number 330598). It was originally reported to VAERS by another manufacturer (Emergent Biosolutions). A 43-year-old male patient received the following vaccination on 07 October 2008: ACAM2000, lot not reported, TYPHIM VI, lot not reported, BIOTHRAX, lot not reported, FLUMIST, lot not reported, and ENGERIX, lot not reported and six days later (also reported as 17 October 2008), he developed acute onset of substernal chest pressure at rest. The pressure became a sharp pain that worsened with deep breathing and also radiated down the left arm. According to the reporter, the patient's symptoms and EKG findings were most consistent with mild pericarditis and a viral syndrome, most likely as a result of the ACAM2000. An echocardiogram was to be performed to assess for a pericardial effusion and to ensure cardiac function was normal. The patient recovered from the event. Documents held by sender: None
Age: 43.0
Sex: M
Vaccine: ANTH, FLUN3, HEP, SMALL, TYP
Symptoms: Viral infection
Clinical narrative: This case was received on 17 December 2008 via a search of the database (reference number 330598). It was originally reported to VAERS by another manufacturer (Emergent Biosolutions). A 43-year-old male patient received the following vaccination on 07 October 2008: ACAM2000, lot not reported, TYPHIM VI, lot not reported, BIOTHRAX, lot not reported, FLUMIST, lot not reported, and ENGERIX, lot not reported and six days later (also reported as 17 October 2008), he developed acute onset of substernal chest pressure at rest. The pressure became a sharp pain that worsened with deep breathing and also radiated down the left arm. According to the reporter, the patient's symptoms and EKG findings were most consistent with mild pericarditis and a viral syndrome, most likely as a result of the ACAM2000. An echocardiogram was to be performed to assess for a pericardial effusion and to ensure cardiac function was normal. The patient recovered from the event. Documents held by sender: None
Age: 48.0
Sex: M
Vaccine: ANTH, HIBV, SMALL, TYP
Symptoms: Abdominal pain, Acne, Agitation, Alopecia, Amblyopia
Clinical narrative: This serious case was received via an extraction of the database on 02 February 2009, under VAERS reference number 333067. A 48-year-old male patient received the following vaccines on an unknown date: TYPHIM VI, smallpox vaccine, haemophilus influenza type B vaccine, and anthrax vaccine (lot numbers, manufacturers, and administration details not reported). The patient subsequently experienced acne, amblyopia, arthralgia, blood cholesterol increased, abdominal pain, agitation, alopecia, amnesia, anorexia, anxiety, aphasia, arthritis, asthenia, balance disorder, blood pressure fluctuation, and bone pain. No additional information was reported.
Age: 48.0
Sex: M
Vaccine: ANTH, HIBV, SMALL, TYP
Symptoms: Amnesia, Anxiety, Aphasia, Arthralgia, Arthritis
Clinical narrative: This serious case was received via an extraction of the database on 02 February 2009, under VAERS reference number 333067. A 48-year-old male patient received the following vaccines on an unknown date: TYPHIM VI, smallpox vaccine, haemophilus influenza type B vaccine, and anthrax vaccine (lot numbers, manufacturers, and administration details not reported). The patient subsequently experienced acne, amblyopia, arthralgia, blood cholesterol increased, abdominal pain, agitation, alopecia, amnesia, anorexia, anxiety, aphasia, arthritis, asthenia, balance disorder, blood pressure fluctuation, and bone pain. No additional information was reported.
Age: 48.0
Sex: M
Vaccine: ANTH, HIBV, SMALL, TYP
Symptoms: Asthenia, Balance disorder, Blood cholesterol increased, Blood pressure fluctuation, Bone pain
Clinical narrative: This serious case was received via an extraction of the database on 02 February 2009, under VAERS reference number 333067. A 48-year-old male patient received the following vaccines on an unknown date: TYPHIM VI, smallpox vaccine, haemophilus influenza type B vaccine, and anthrax vaccine (lot numbers, manufacturers, and administration details not reported). The patient subsequently experienced acne, amblyopia, arthralgia, blood cholesterol increased, abdominal pain, agitation, alopecia, amnesia, anorexia, anxiety, aphasia, arthritis, asthenia, balance disorder, blood pressure fluctuation, and bone pain. No additional information was reported.
Age: 48.0
Sex: M
Vaccine: ANTH, HIBV, SMALL, TYP
Symptoms: Decreased appetite
Clinical narrative: This serious case was received via an extraction of the database on 02 February 2009, under VAERS reference number 333067. A 48-year-old male patient received the following vaccines on an unknown date: TYPHIM VI, smallpox vaccine, haemophilus influenza type B vaccine, and anthrax vaccine (lot numbers, manufacturers, and administration details not reported). The patient subsequently experienced acne, amblyopia, arthralgia, blood cholesterol increased, abdominal pain, agitation, alopecia, amnesia, anorexia, anxiety, aphasia, arthritis, asthenia, balance disorder, blood pressure fluctuation, and bone pain. No additional information was reported.
Age: 51.0
Sex: M
Vaccine: ANTH, HEP, SMALL, TYP
Symptoms: Amnesia, Arthralgia, Blood creatine phosphokinase normal, Cough, Dizziness
Clinical narrative: This case was received by Sanofi Pasteur on 07 May 2009 via a QScan search on the VAERS, under reference number 340152. A 51 year old male received TYPHIM VI (lot number not reported) smallpox vaccine (other manufacturer, lot number not reported), BIOTHRAX (Emergent Biosolutions, lot number not reported) and ENGERIX-B, GlaxoSmithKline, lot number not reported). The date of vaccination was reported as 2007. The patient reports that since receiving vaccines in 2007, he continues to experience cough, fatigue, myalgia, arthralgia, dizziness and short term memory loss. An electrocardiogram showed normal sinus rhythm with (0-2.37); troponin I <0.38 (0-0.08); K 5.1 (3.6-5.0); and ESR 17 (normal range not reported). Two results were reported for monocytes: 9.8 and 12.2 (1.7-9.3). All other CBC, chemistry and urine analysis parameters were reported as within normal limits. No additional information was provided. Although the smallpox vaccine manufacturer was reported as unknown in this case, ACAM2000 was not available for use at the time of the patient's vaccination.
Age: 51.0
Sex: M
Vaccine: ANTH, HEP, SMALL, TYP
Symptoms: Electrocardiogram normal, Fatigue, Full blood count normal, Laboratory test normal, Myalgia
Clinical narrative: This case was received by Sanofi Pasteur on 07 May 2009 via a QScan search on the VAERS, under reference number 340152. A 51 year old male received TYPHIM VI (lot number not reported) smallpox vaccine (other manufacturer, lot number not reported), BIOTHRAX (Emergent Biosolutions, lot number not reported) and ENGERIX-B, GlaxoSmithKline, lot number not reported). The date of vaccination was reported as 2007. The patient reports that since receiving vaccines in 2007, he continues to experience cough, fatigue, myalgia, arthralgia, dizziness and short term memory loss. An electrocardiogram showed normal sinus rhythm with (0-2.37); troponin I <0.38 (0-0.08); K 5.1 (3.6-5.0); and ESR 17 (normal range not reported). Two results were reported for monocytes: 9.8 and 12.2 (1.7-9.3). All other CBC, chemistry and urine analysis parameters were reported as within normal limits. No additional information was provided. Although the smallpox vaccine manufacturer was reported as unknown in this case, ACAM2000 was not available for use at the time of the patient's vaccination.
Age: 51.0
Sex: M
Vaccine: ANTH, HEP, SMALL, TYP
Symptoms: Red blood cell sedimentation rate normal
Clinical narrative: This case was received by Sanofi Pasteur on 07 May 2009 via a QScan search on the VAERS, under reference number 340152. A 51 year old male received TYPHIM VI (lot number not reported) smallpox vaccine (other manufacturer, lot number not reported), BIOTHRAX (Emergent Biosolutions, lot number not reported) and ENGERIX-B, GlaxoSmithKline, lot number not reported). The date of vaccination was reported as 2007. The patient reports that since receiving vaccines in 2007, he continues to experience cough, fatigue, myalgia, arthralgia, dizziness and short term memory loss. An electrocardiogram showed normal sinus rhythm with (0-2.37); troponin I <0.38 (0-0.08); K 5.1 (3.6-5.0); and ESR 17 (normal range not reported). Two results were reported for monocytes: 9.8 and 12.2 (1.7-9.3). All other CBC, chemistry and urine analysis parameters were reported as within normal limits. No additional information was provided. Although the smallpox vaccine manufacturer was reported as unknown in this case, ACAM2000 was not available for use at the time of the patient's vaccination.
Age: 28.0
Sex: M
Vaccine: SMALL, TYP
Symptoms: Disability, Dysgraphia, Electromyogram, Facial palsy, Feeling cold
Clinical narrative: This case was received on 26 June 2009 via a search of the VAERS database (reference number 343838). A 28 year old male patient received the following vaccinations on 10 December 2003; TYPHIM VI (lot not reported), small pox, anthrax, and HEPATITIS A and B (manufacturer and lot not reported). Approximately 4 weeks post vaccination, on 01 January 2004 the patient had symptoms of coldness, numbness and twitching of the left side of the face. The patient lost expression on the left side of his face. Within 6 months, the patient was diagnosed with Bell's Palsy at local facility and was hospitalized. The patient was given 2 grams on ROCEPHIN IV for approximately 6 weeks during and post hospitalization. Symptoms gradually subsided but still has occasional coldness, twitching of the left side of the face. Despite diagnosis of Bell's Palsy with possible relationship to vaccines, he was given second ANTHRAX immunization on 15 September 2004 along with the second dose of HEPATITIS A and B. The patient was deployed in October 2004. Beginning October, November 2004 patient developed stiffness, pain and swelling of ankles, feet, knees, hands, shoulders, elbows, lower back. The symptoms ebbed and flowed but pain and swelling in knees, wrists, hands had gradually increased in intensity to average 7/10 pain level. Able to function fairly well with pain 5-6/10 level, but not higher. The most recent ESR and CSC (08 Apr 2009) were within normal limits. Rheumatology labs from facility drawn with the last 6 months. EMG is pending. The outcome was reported as disability, emergency room/doctor visit, and hospitalized. Upon internal review on 23 October 2009, a corrective version of the case was created to amend information received on 26 June 2009. The manufacturer of smallpox vaccine was changed from "manufacturer unknown" to "other manufacturer". Although the smallpox vaccine manufacturer was reported as unknown in this case, ACAM2000 was not available for use at the time of the patient's vaccination. List of Documents held by Sender: none.
Age: 28.0
Sex: M
Vaccine: SMALL, TYP
Symptoms: Full blood count normal, Hypoaesthesia facial, Laboratory test, Muscle twitching, Musculoskeletal stiffness
Clinical narrative: This case was received on 26 June 2009 via a search of the VAERS database (reference number 343838). A 28 year old male patient received the following vaccinations on 10 December 2003; TYPHIM VI (lot not reported), small pox, anthrax, and HEPATITIS A and B (manufacturer and lot not reported). Approximately 4 weeks post vaccination, on 01 January 2004 the patient had symptoms of coldness, numbness and twitching of the left side of the face. The patient lost expression on the left side of his face. Within 6 months, the patient was diagnosed with Bell's Palsy at local facility and was hospitalized. The patient was given 2 grams on ROCEPHIN IV for approximately 6 weeks during and post hospitalization. Symptoms gradually subsided but still has occasional coldness, twitching of the left side of the face. Despite diagnosis of Bell's Palsy with possible relationship to vaccines, he was given second ANTHRAX immunization on 15 September 2004 along with the second dose of HEPATITIS A and B. The patient was deployed in October 2004. Beginning October, November 2004 patient developed stiffness, pain and swelling of ankles, feet, knees, hands, shoulders, elbows, lower back. The symptoms ebbed and flowed but pain and swelling in knees, wrists, hands had gradually increased in intensity to average 7/10 pain level. Able to function fairly well with pain 5-6/10 level, but not higher. The most recent ESR and CSC (08 Apr 2009) were within normal limits. Rheumatology labs from facility drawn with the last 6 months. EMG is pending. The outcome was reported as disability, emergency room/doctor visit, and hospitalized. Upon internal review on 23 October 2009, a corrective version of the case was created to amend information received on 26 June 2009. The manufacturer of smallpox vaccine was changed from "manufacturer unknown" to "other manufacturer". Although the smallpox vaccine manufacturer was reported as unknown in this case, ACAM2000 was not available for use at the time of the patient's vaccination. List of Documents held by Sender: none.
Age: 28.0
Sex: M
Vaccine: SMALL, TYP
Symptoms: Pain, Red blood cell sedimentation rate normal, Swelling
Clinical narrative: This case was received on 26 June 2009 via a search of the VAERS database (reference number 343838). A 28 year old male patient received the following vaccinations on 10 December 2003; TYPHIM VI (lot not reported), small pox, anthrax, and HEPATITIS A and B (manufacturer and lot not reported). Approximately 4 weeks post vaccination, on 01 January 2004 the patient had symptoms of coldness, numbness and twitching of the left side of the face. The patient lost expression on the left side of his face. Within 6 months, the patient was diagnosed with Bell's Palsy at local facility and was hospitalized. The patient was given 2 grams on ROCEPHIN IV for approximately 6 weeks during and post hospitalization. Symptoms gradually subsided but still has occasional coldness, twitching of the left side of the face. Despite diagnosis of Bell's Palsy with possible relationship to vaccines, he was given second ANTHRAX immunization on 15 September 2004 along with the second dose of HEPATITIS A and B. The patient was deployed in October 2004. Beginning October, November 2004 patient developed stiffness, pain and swelling of ankles, feet, knees, hands, shoulders, elbows, lower back. The symptoms ebbed and flowed but pain and swelling in knees, wrists, hands had gradually increased in intensity to average 7/10 pain level. Able to function fairly well with pain 5-6/10 level, but not higher. The most recent ESR and CSC (08 Apr 2009) were within normal limits. Rheumatology labs from facility drawn with the last 6 months. EMG is pending. The outcome was reported as disability, emergency room/doctor visit, and hospitalized. Upon internal review on 23 October 2009, a corrective version of the case was created to amend information received on 26 June 2009. The manufacturer of smallpox vaccine was changed from "manufacturer unknown" to "other manufacturer". Although the smallpox vaccine manufacturer was reported as unknown in this case, ACAM2000 was not available for use at the time of the patient's vaccination. List of Documents held by Sender: none.
Age: 31.0
Sex: F
Vaccine: HEPA, TDAP, TYP
Symptoms: Mobility decreased, Neck pain
Clinical narrative: Initial report received 19 February 2009 from a health care professional. A 31-year-old female patient with known allergies to penicillin and cephalosporins, had received an intramuscular right deltoid injection of Adacel, lot number C3032AA, and an intramuscular left deltoid injection of Typhim Vi, lot number B0424-2, and an intramuscular right deltoid injection of Havrix, lot number AHAVB275AA on 06 February 2009 and on the day of vaccination, she experienced pain radiating to her neck and down to her hand resulting in limited mobility. The patient was evaluated at a walk-in clinic (date not reported) and prescribed a sling. The patient was also evaluated by a chiropractor and acupuncturist (dates not reported). At the time of the report, her recovery status was unknown. No additional information was provided. Follow-up information was received 27 April 2009 from a health case professional who reported that they had no additional information to provide. The patient had returned to her home country and no forwarding address was left. Follow-up information was received from the health care professional on 29 June 2009. The information had been reviewed, and the reporter had no additional information to provided. Documents held by sender: None.
Age: 37.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Blood creatine phosphokinase normal, Chest discomfort, Chest pain, Echocardiogram normal, Haematocrit normal
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 352754. A 37 year old male patient received the following vaccines on 10 July 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04-003A); an intramuscular injection of TYPHIM VI (lot number B07062); and anthrax vaccine (manufacturer unknown, lot number FAV177). Sites of administration were not reported. Twelve days after vaccination the patient was diagnosed with myocarditis and admitted to the hospital. The patient first noticed some chest discomfort on Day 10 which was attributed to indigestion. A few hours later, he developed severe chest pain (8 out of 10 on a pain scale). The patient was seen in the Emergency Room where he was diagnosed with myocarditis by elevated troponin levels and was admitted. The patient had a normal echocardiogram and was discharged the following day with instructions to follow-up with cardiology. Lab results include: Troponin T Cardiac, 0.041 (H*); Creatine Kinase, 127 U/L; WBC, 10.0 x 10(3)/mcL; RBC, 4.52 x 10(6)/mcL; Hemoglobin, 14.6 g/dl; Hematocrit, 42.4%; MCV, 91.8 fl; MCH ,31.6 pg; and MCHC, 34.4 g/d. The patient had a normal echocardiogram. The patient revered. List of documents held by sender: none.
Age: 37.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Haemoglobin normal, Mean cell haemoglobin concentration normal, Mean cell haemoglobin increased, Mean cell volume normal, Myocarditis
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 352754. A 37 year old male patient received the following vaccines on 10 July 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04-003A); an intramuscular injection of TYPHIM VI (lot number B07062); and anthrax vaccine (manufacturer unknown, lot number FAV177). Sites of administration were not reported. Twelve days after vaccination the patient was diagnosed with myocarditis and admitted to the hospital. The patient first noticed some chest discomfort on Day 10 which was attributed to indigestion. A few hours later, he developed severe chest pain (8 out of 10 on a pain scale). The patient was seen in the Emergency Room where he was diagnosed with myocarditis by elevated troponin levels and was admitted. The patient had a normal echocardiogram and was discharged the following day with instructions to follow-up with cardiology. Lab results include: Troponin T Cardiac, 0.041 (H*); Creatine Kinase, 127 U/L; WBC, 10.0 x 10(3)/mcL; RBC, 4.52 x 10(6)/mcL; Hemoglobin, 14.6 g/dl; Hematocrit, 42.4%; MCV, 91.8 fl; MCH ,31.6 pg; and MCHC, 34.4 g/d. The patient had a normal echocardiogram. The patient revered. List of documents held by sender: none.
Age: 37.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Red blood cell count decreased, Troponin T increased, White blood cell count normal
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 352754. A 37 year old male patient received the following vaccines on 10 July 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04-003A); an intramuscular injection of TYPHIM VI (lot number B07062); and anthrax vaccine (manufacturer unknown, lot number FAV177). Sites of administration were not reported. Twelve days after vaccination the patient was diagnosed with myocarditis and admitted to the hospital. The patient first noticed some chest discomfort on Day 10 which was attributed to indigestion. A few hours later, he developed severe chest pain (8 out of 10 on a pain scale). The patient was seen in the Emergency Room where he was diagnosed with myocarditis by elevated troponin levels and was admitted. The patient had a normal echocardiogram and was discharged the following day with instructions to follow-up with cardiology. Lab results include: Troponin T Cardiac, 0.041 (H*); Creatine Kinase, 127 U/L; WBC, 10.0 x 10(3)/mcL; RBC, 4.52 x 10(6)/mcL; Hemoglobin, 14.6 g/dl; Hematocrit, 42.4%; MCV, 91.8 fl; MCH ,31.6 pg; and MCHC, 34.4 g/d. The patient had a normal echocardiogram. The patient revered. List of documents held by sender: none.
Age: 37.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Blood creatine phosphokinase normal, Chest discomfort, Chest pain, Dyspepsia, Echocardiogram normal
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 352754. A 37 year old male patient received the following vaccines on 10 July 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04-003A); an intramuscular injection of TYPHIM VI (lot number B07062); and anthrax vaccine (manufacturer unknown, lot number FAV177). Sites of administration were not reported. Twelve days after vaccination the patient was diagnosed with myocarditis and admitted to the hospital. The patient first noticed some chest discomfort on Day 10 which was attributed to indigestion. A few hours later, he developed severe chest pain (8 out of 10 on a pain scale). The patient was seen in the Emergency Room where he was diagnosed with myocarditis by elevated troponin levels and was admitted. The patient had a normal echocardiogram and was discharged the following day with instructions to follow-up with cardiology. Lab results include: Troponin T Cardiac, 0.041 (H*); Creatine Kinase, 127 U/L; WBC, 10.0 x 10(3)/mcL; RBC, 4.52 x 10(6)/mcL; Hemoglobin, 14.6 g/dl; Hematocrit, 42.4%; MCV, 91.8 fl; MCH ,31.6 pg; and MCHC, 34.4 g/d. The patient had a normal echocardiogram. The patient revered. List of documents held by sender: none.
Age: 37.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Haematocrit normal, Haemoglobin normal, Mean cell haemoglobin concentration normal, Mean cell haemoglobin increased, Mean cell volume normal
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 352754. A 37 year old male patient received the following vaccines on 10 July 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04-003A); an intramuscular injection of TYPHIM VI (lot number B07062); and anthrax vaccine (manufacturer unknown, lot number FAV177). Sites of administration were not reported. Twelve days after vaccination the patient was diagnosed with myocarditis and admitted to the hospital. The patient first noticed some chest discomfort on Day 10 which was attributed to indigestion. A few hours later, he developed severe chest pain (8 out of 10 on a pain scale). The patient was seen in the Emergency Room where he was diagnosed with myocarditis by elevated troponin levels and was admitted. The patient had a normal echocardiogram and was discharged the following day with instructions to follow-up with cardiology. Lab results include: Troponin T Cardiac, 0.041 (H*); Creatine Kinase, 127 U/L; WBC, 10.0 x 10(3)/mcL; RBC, 4.52 x 10(6)/mcL; Hemoglobin, 14.6 g/dl; Hematocrit, 42.4%; MCV, 91.8 fl; MCH ,31.6 pg; and MCHC, 34.4 g/d. The patient had a normal echocardiogram. The patient revered. List of documents held by sender: none.
Age: 37.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Myocarditis, Red blood cell count decreased, Troponin T increased, White blood cell count normal
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 352754. A 37 year old male patient received the following vaccines on 10 July 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04-003A); an intramuscular injection of TYPHIM VI (lot number B07062); and anthrax vaccine (manufacturer unknown, lot number FAV177). Sites of administration were not reported. Twelve days after vaccination the patient was diagnosed with myocarditis and admitted to the hospital. The patient first noticed some chest discomfort on Day 10 which was attributed to indigestion. A few hours later, he developed severe chest pain (8 out of 10 on a pain scale). The patient was seen in the Emergency Room where he was diagnosed with myocarditis by elevated troponin levels and was admitted. The patient had a normal echocardiogram and was discharged the following day with instructions to follow-up with cardiology. Lab results include: Troponin T Cardiac, 0.041 (H*); Creatine Kinase, 127 U/L; WBC, 10.0 x 10(3)/mcL; RBC, 4.52 x 10(6)/mcL; Hemoglobin, 14.6 g/dl; Hematocrit, 42.4%; MCV, 91.8 fl; MCH ,31.6 pg; and MCHC, 34.4 g/d. The patient had a normal echocardiogram. The patient revered. List of documents held by sender: none.
Age: 0.12
Sex: F
Vaccine: FLU(H1N1), FLU3
Symptoms: Asthenia, Electromyogram abnormal, Guillain-Barre syndrome, Inappropriate schedule of drug administration
Clinical narrative: Initial case received from the US Centers for Disease Control and Prevention (CDC) on 08 January 2010, under VAERS ID number 374199-1. This report involved a case of misuse; influenza vaccines are not indicated for children under the age of 6 months. A 7-week-old female patient had received an injection of FLUZONE No Preservative 2009-2010 (lot number U3263CA) and an injection of Influenza A (H1N1) 2009 Monovalent Vaccine - No Preservative (lot number UT023FA) on 20 November 2009 (dose number, routes and sites of administration were not reported). Seven days later, she developed progressive weakness and was hospitalized. The length of the hospitalization was not reported. the patient had an EMG performed which deemed abnormal and consistent with AIDP (acute inflammatory demyelinating polyneuropathy) and was diagnosed with Guillain Barre Syndrome. The patient recovered. Documents held by sender: None.
Age: 60.0
Sex: M
Vaccine: FLU(H1N1), FLU(H1N1)
Symptoms: Burning sensation, Erythema, Oedema peripheral, Rash macular
Clinical narrative: Both back of hands developed burning red rash, right forearm also had burning red rash. Incident developed several hours after injection.
Age: 60.0
Sex: M
Vaccine: FLU(H1N1), FLU(H1N1)
Symptoms: Burning sensation, Rash erythematous
Clinical narrative: Both back of hands developed burning red rash, right forearm also had burning red rash. Incident developed several hours after injection.
Age: 5.0
Sex: F
Vaccine: DTAP, IPV, DTAP, IPV
Symptoms: Agitation, Cough, Flushing, Respiratory distress, Wheezing
Clinical narrative: Initial report received on 14 January 2010 from a healthcare professional. A 5 year old female patient with a history of multiple arterial aneurysms, asthma, environmental and food allergies, hydronephrosis, anaphylaxis with pulmicort developed flushing, coughing, wheezing, respiratory distress, and agitation approximately 10 minutes after she received an intramuscular fifth dose of DAPTACEL (lot C3191AA) and a subcutaneous fourth dose of IPOL (lot D0480) on 13 January 2010 at 11:00 AM. On 05 January 2010 the patient received a second intramuscular dose in the left arm of H1N1 (lot UP071AA). The patient was transported to the emergency room by EMS. The patient was treated with BENADRYL, XOPENEX, and EPIPEN. The patient recovered. Concomitant therapy included NASONEX, calcium, and aspirin. Follow-up information received on 15 January 2010 from a consumer (patient's parent) who reported that the medication administered in the doctor's office, which was BENADRYL and a breathing treatment, were not effective. Therefore, additional treatment was received in the emergency room where the patient was given epinephrine. Additional symptoms included difficulty breathing and swollen lips and eyes. Following the administration of epinephrine, the patient's symptoms resolved completely. The emergency room visit was 5 hours in duration. The reporter also stated that the event began 2-3 minutes post vaccination, previously reported as 10 minutes post vaccination. No further information was provided.
Age: 5.0
Sex: F
Vaccine: DTAP, IPV, DTAP, IPV
Symptoms: Agitation, Aneurysm, Cough, Dyspnoea, Eye swelling
Clinical narrative: Initial report received on 14 January 2010 from a healthcare professional. A 5 year old female patient with a history of multiple arterial aneurysms, asthma, environmental and food allergies, hydronephrosis, anaphylaxis with pulmicort developed flushing, coughing, wheezing, respiratory distress, and agitation approximately 10 minutes after she received an intramuscular fifth dose of DAPTACEL (lot C3191AA) and a subcutaneous fourth dose of IPOL (lot D0480) on 13 January 2010 at 11:00 AM. On 05 January 2010 the patient received a second intramuscular dose in the left arm of H1N1 (lot UP071AA). The patient was transported to the emergency room by EMS. The patient was treated with BENADRYL, XOPENEX, and EPIPEN. The patient recovered. Concomitant therapy included NASONEX, calcium, and aspirin. Follow-up information received on 15 January 2010 from a consumer (patient's parent) who reported that the medication administered in the doctor's office, which was BENADRYL and a breathing treatment, were not effective. Therefore, additional treatment was received in the emergency room where the patient was given epinephrine. Additional symptoms included difficulty breathing and swollen lips and eyes. Following the administration of epinephrine, the patient's symptoms resolved completely. The emergency room visit was 5 hours in duration. The reporter also stated that the event began 2-3 minutes post vaccination, previously reported as 10 minutes post vaccination. No further information was provided.
Age: 5.0
Sex: F
Vaccine: DTAP, IPV, DTAP, IPV
Symptoms: Flushing, Lip swelling, Respiratory distress, Wheezing
Clinical narrative: Initial report received on 14 January 2010 from a healthcare professional. A 5 year old female patient with a history of multiple arterial aneurysms, asthma, environmental and food allergies, hydronephrosis, anaphylaxis with pulmicort developed flushing, coughing, wheezing, respiratory distress, and agitation approximately 10 minutes after she received an intramuscular fifth dose of DAPTACEL (lot C3191AA) and a subcutaneous fourth dose of IPOL (lot D0480) on 13 January 2010 at 11:00 AM. On 05 January 2010 the patient received a second intramuscular dose in the left arm of H1N1 (lot UP071AA). The patient was transported to the emergency room by EMS. The patient was treated with BENADRYL, XOPENEX, and EPIPEN. The patient recovered. Concomitant therapy included NASONEX, calcium, and aspirin. Follow-up information received on 15 January 2010 from a consumer (patient's parent) who reported that the medication administered in the doctor's office, which was BENADRYL and a breathing treatment, were not effective. Therefore, additional treatment was received in the emergency room where the patient was given epinephrine. Additional symptoms included difficulty breathing and swollen lips and eyes. Following the administration of epinephrine, the patient's symptoms resolved completely. The emergency room visit was 5 hours in duration. The reporter also stated that the event began 2-3 minutes post vaccination, previously reported as 10 minutes post vaccination. No further information was provided.
Age: 1.06
Sex: M
Vaccine: HEPA, MMR, VARCEL
Symptoms: Dyspnoea, Febrile convulsion, Pyrexia, Rash, Respiratory arrest
Clinical narrative: Spiking fever uncontrollable with Tylenol, febrile seizure about 6 hours later, trouble breathing and eventually not breathing before and during seizure, after seizure continuation of spiking fever for about 15 hours. After fever was under control a mumps like rash developed and lasted for 7 days.
Age: 1.49
Sex: M
Vaccine: DTAP
Symptoms: Injection site erythema, Injection site nodule, Injection site swelling, Pyrexia
Clinical narrative: Fever, large red hot swollen bump at shot site, about the size of a small apple.
Age: 14.0
Sex: F
Vaccine: HPV4
Symptoms: Dizziness, Hypoacusis, Syncope
Clinical narrative: Approx. 5 minutes after administration of Gardasil vaccine, patient left doctors office with her mom, she suddently said I feel everywhere is white then she felt that she is not hearing anything, she said I feel dizzy and then she fainted for about 5 seconds. Her mom held her and avoided her collapse.
Age: 0.36
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Cyanosis, Hypotonia, Skin discolouration
Clinical narrative: Pt had temperature of 99.0F at 8:00pm, gave Tylenol at 8:20pm.  At 8:30pm, mom reports pt became completely limp, turned white, with bluish change to lips.  Patient's eyes were closes, he was breathing, and still arousable, but limp.  Mom called 911, episode lasted about 5-6 minutes, then resolved completely.  Following, patient's vitals were stable, he was awake and fed well.  No convulsions or postictal state.
Age: 43.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Arthralgia, Chest pain, Dyspnoea, Eosinophil count increased, Hypertension
Clinical narrative: SOB, CP, myalgias, arthralgias, upper extremity rash, tachycardia, HTN
Age: 43.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Myalgia, Rash, Tachycardia
Clinical narrative: SOB, CP, myalgias, arthralgias, upper extremity rash, tachycardia, HTN
Age: 11.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Coagulation test abnormal, Cognitive disorder, Dysarthria, Electroencephalogram abnormal, Facial paresis
Clinical narrative: Slurred speech, right arm and facial weakness, decreased cognitive function.
Age: 11.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Muscular weakness, Nuclear magnetic resonance imaging brain abnormal
Clinical narrative: Slurred speech, right arm and facial weakness, decreased cognitive function.